Health & Fitness
Health and Fitness
Health and Fitness
Thu, October 20, 2011
Wed, October 19, 2011
Release Of Cannabis Science Brand Formulations Align With History Being Made as California Medical Association New Policy And W
DENVER--([ BUSINESS WIRE ])--Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the California Medical Association has adopted an official policy recommending legalizing and regulating cannabis and American History is made, for the first time over 50% of Americans are supporting legalizing Marijuana in new Washington Gallop Poll.
Please visit: [ http://www.gallup.com/poll/150149/Record-High-Americans-Favor-Legalizing-Marijuana.aspx ] to see American Marijuana History in the Making.
Please visit: [ http://news.yahoo.com/california-medical-association-wants-marijuana-legalized ] to read the California Medical Association article in full.
The announcement occurs on the heals of Cannabis Science receiving its first samples of its new formulation that is now ready for market release. The Company has been receiving a constant flow of inquires via its website, emails, and telephone calls for cannabis-extract based medicines. For example, cancer patients seeking extract-based formulations for topical or internal use have frequently contacted Cannabis Science. We have responded to these patient requests for quality products. In the next few days, Cannabis Science will announce details of the much-anticipated official release date along with patient accessibility options.
In light of the accumulating anecdotal reports of the successful cancer treatments with cannabis extracts, the Company will continue to keep patients updated on current peer-reviewed scientific literature supporting the historical and modern use of cannabis to treat "tumorsa. Unlike conventional treatment, cannabis medicines have an outstanding safety profile allowing patients in states with medical marijuana laws to safely make informed decisions to legally self-administration of various cannabis-based preparations.
Dr. Melamede states, aIn line with the California Medical Associationa™s announcement, national opinion surveys have shown for the first-time that 50% of Americans now support the decriminalization of marijuana. We see a general awakening of public awareness that marijuana does not belong in the class I schedule. This awareness will eventually translate into new governmental policies that will facilitate research and development of cannabis based pharmaceutical products for the benefit mankind. Because of the unique and all pervasive nature of the human endocannabinoid system, there are numerous opportunities for the development of novel, organic, holistic medicines from this plant.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The first formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
